
==== Front
Esophagus
Esophagus
Esophagus
1612-9059
1612-9067
Springer Nature Singapore Singapore

38990441
1072
10.1007/s10388-024-01072-w
Original Article
A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma
Makino Tomoki 1
Miyata Hiroshi 2
http://orcid.org/0000-0003-4025-8113
Yasuda Takushi takushi-yasuda6008@med.kindai.ac.jp

3
Kitagawa Yuko 4
Muro Kei 5
Park Jae-Hyun 6
Hikichi Tetsuro 7
Hasegawa Takahiro 8
Igarashi Kenji 9
Iguchi Motofumi 10
Masaoka Yasuhide 11
Yano Masahiko 212
Doki Yuichiro 1
1 https://ror.org/035t8zc32 grid.136593.b 0000 0004 0373 3971 Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan
2 https://ror.org/010srfv22 grid.489169.b Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
3 https://ror.org/05kt9ap64 grid.258622.9 0000 0004 1936 9967 Department of Surgery, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka 589-8511 Japan
4 https://ror.org/02kn6nx58 grid.26091.3c 0000 0004 1936 9959 Department of Surgery, Keio University School of Medicine, Tokyo, Japan
5 https://ror.org/03kfmm080 grid.410800.d 0000 0001 0722 8444 Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi Japan
6 https://ror.org/000znbq58 grid.480306.9 OncoTherapy Science, Inc., Kawasaki, Kanagawa Japan
7 Laboratory Department, Cancer Precision Medicine, Inc., Kawasaki, Kanagawa Japan
8 grid.419164.f 0000 0001 0665 2737 Biostatistics Center, Shionogi & Co., Ltd., Osaka, Japan
9 grid.419164.f 0000 0001 0665 2737 Project Management, Shionogi & Co., Ltd., Osaka, Japan
10 grid.419164.f 0000 0001 0665 2737 Medical Affairs Department, Shionogi & Co., Ltd, Osaka, Japan
11 grid.419164.f 0000 0001 0665 2737 Clinical Development, Shionogi & Co., Ltd, Osaka, Japan
12 Present Address: Kyowakai Hospital, Osaka, Japan
11 7 2024
11 7 2024
2024
21 4 447455
30 4 2024
2 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

S-588410, a cancer peptide vaccine (CPV), comprises five HLA-A*24:02-restricted peptides from five cancer-testis antigens. In a phase 2 study, S-588410 was well-tolerated and exhibited antitumor efficacy in patients with urothelial cancer. Therefore, we aimed to evaluate the efficacy, immune response, and safety of S-588410 in patients with completely resected esophageal squamous cell carcinoma (ESCC).

Methods

This phase 3 study involved patients with HLA-A*24:02-positive and lymph node metastasis-positive ESCC who received neoadjuvant therapy followed by curative resection. After randomization, patients were administered S-588410 and placebo (both emulsified with Montanide™ ISA 51VG) subcutaneously. The primary endpoint was relapse-free survival (RFS). The secondary endpoints were overall survival (OS), cytotoxic T-lymphocyte (CTL) induction, and safety. Statistical significance was tested using the one-sided weighted log-rank test with the Fleming–Harrington class of weights.

Results

A total of 276 patients were randomized (N = 138/group). The median RFS was 84.3 and 84.1 weeks in the S-588410 and placebo groups, respectively (P = 0.8156), whereas the median OS was 236.3 weeks and not reached, respectively (P = 0.6533). CTL induction was observed in 132/134 (98.5%) patients who received S-588410 within 12 weeks. Injection site reactions (137/140 patients [97.9%]) were the most frequent treatment-emergent adverse events in the S-588410 group. Prolonged survival was observed in S-588410-treated patients with upper thoracic ESCC, grade 3 injection-site reactions, or high CTL intensity.

Conclusions

S-588410 induced immune response and had acceptable safety but failed to reach the primary endpoint. A high CTL induction rate and intensity may be critical for prolonging survival during future CPV development.

Supplementary Information

The online version contains supplementary material available at 10.1007/s10388-024-01072-w.

Keywords

Esophageal squamous cell carcinoma
Adjuvant therapy
Cytotoxic T lymphocytes
Cancer peptide vaccine
S-588410
OncoTherapy Science Inc.http://dx.doi.org/10.13039/501100005612 Shionogi issue-copyright-statement© The Japan Esophageal Society 2024
==== Body
pmcIntroduction

According to the Global Cancer Statistics 2020, esophageal cancer had 604,100 new cases and approximately 544,100 associated deaths, with the highest incidence and mortality documented in Eastern Asia [1]. By 2040, the incidence of esophageal cancer and the associated mortality is estimated to increase by 58% and 62% worldwide, respectively [2]. In contrast to Europe and the United States, Asia, including Japan, has a higher number of patients with esophageal squamous cell carcinoma (ESCC) than those with adenocarcinoma [2]; hence, treatment approaches and outcomes tend to differ across regions [3].

Surgery remains a major treatment strategy for locally advanced resectable esophageal cancers, and reports have suggested that the addition of preoperative or postoperative therapy to surgery could substantially improve patient survival [4, 5]. The Esophagus 2022 Guidelines for Diagnosis and Treatment of Carcinoma recommend nivolumab and pembrolizumab, both anti-programmed cell death (PD)-1 antibodies for patients with advanced or metastatic esophageal cancer. Moreover, adjuvant therapy with nivolumab has recently been approved for patients with stage II or III esophageal or gastroesophageal junction cancer who have received neoadjuvant chemotherapy and have residual pathological disease [6]. The efficacy of anti-PD-1 antibodies is associated with the presence of tumor-infiltrating lymphocytes (TILs) and the expression of programmed death ligand 1 (PD-L1) in tumors [7].

HLA-A*24:02 is one of the most frequently observed HLA-A alleles in Asian races with a particularly high frequency in Japanese individuals (approximately 60%) [8]. Previously, a cancer vaccine comprising three HLA-A*24:02-restricted peptides derived from three antigens, i.e., lymphocyte antigen-6 complex locus (LY6k, also known as upregulated lung cancer 10; URLC10), TTK protein kinase, and insulin-like growth factor-II mRNA binding protein-3 (IMP3, also known as KH domain-containing protein overexpressed in cancer 1; KOC1), was found to prolong survival and induce antigen-specific cytotoxic T lymphocytes (CTLs) in patients with ESCC with locally advanced, recurrent, or/and metastatic tumors who failed to respond to the standard therapy [9]. An investigator-initiated phase 2 study on three HLA-A*24:02-restricted peptides from URLC10, KOC1, and cell division cycle-associated protein 1 (CDCA1) demonstrated prolonged survival of patients with esophageal cancer presenting pathologically positive nodes and curatively resected after preoperative therapy [10]. Another cancer vaccine comprising two HLA-A*24:02-restricted peptides from DEP domain containing 1 (DEPDC1) and M-phase phosphoprotein 1 (MPHOSPH1) afforded prolonged survival in CTL-induced patients with advanced urothelial carcinoma of the bladder [11]. Initially, clinical trials were conducted on a vaccine containing DEPDC1- and MPHOSPH1-derived peptides for bladder cancer patients, who frequently express these two antigens. Meanwhile, a vaccine containing URLC10-, CDCA1-, and KOC1-derived peptides were used in clinical trials for esophageal and lung cancer patients, who frequently express these three antigens. However, since it was revealed that all five antigens were expressed in bladder and esophageal cancer [12, 13], a five-peptide vaccine, S-588410, was determined to be developed for a cancer vaccine against esophageal cancer. The development of cancer peptide vaccines to date has led to the recognition of the heterogeneity of cancer, in which antigen expression patterns differ from patient to patient and from cancer cell to cancer cell, and the immune response (CTL induction) to each peptide that differs from patient to patient [14, 15]. Therefore, vaccines containing peptides derived from multiple antigens are expected to be highly effective in a wider range of patients.

The S-588410 comprises five HLA-A*24:02-restricted peptides from cancer-testis antigens (URLC10, CDCA1, KOC1, DEPDC1, and MPHOSPH1) [16, 17]. It can increase the number of antigen-specific CTLs in the blood and promote CTL recruitment at the tumor site in the esophagus as TILs. Hence, S-588410 could be effective in patients with esophageal cancer [16]. Given that S-588410 was well-tolerated and exhibited antitumor efficacy in certain patients with urothelial cancer in a phase 2 study as a maintenance therapy, this vaccine may address the unmet need for adjuvant therapy in patients with cancer [17]. Accordingly, in the current randomized, placebo-controlled phase 3 study, we aimed to evaluate the efficacy, immune response, and safety of S-588410 as an adjuvant monotherapy for HLA-A*24:02-positive patients with completely resected ESCC.

Methods

Study design, vaccination, and ethics

This randomized, double-blind, multicenter, placebo-controlled study comprised four periods. The study duration was a minimum of 144 weeks and a maximum of approximately 5 years (96-week treatment period, 48-week post-treatment observation period, and follow-up period of up to 3 years after enrollment of the last participant). Eligible participants were enrolled and randomized at a ratio of 1:1 to the S-588410 or placebo group after HLA-A genotyping (Fig., Online Resource 1).

The participants were subcutaneously administered 1 mL of S-588410 emulsion, including 1 mg of each of the five peptides (URLC10, CDCA1, KOC1, DEPDC1, and MPHOSPH1) in Montanide™ ISA 51 VG (Seppic S.A., Paris, France), or 1 mL of placebo emulsion in Montanide™ ISA 51 VG into the inguinal, axillary, or cervical region once weekly for 12 weeks, followed by once every 2 weeks for 94 weeks.

This study (clinical trial number: UMIN000016954) was conducted across 55 centers in Japan in accordance with the International Council for Harmonization Good Clinical Practice and the guiding principles of the Declaration of Helsinki and was approved by the Institutional Review Board or Independent Ethics Committees and health authorities (Shionogi Ethical Committee: November 15, 2014). Written informed consent was obtained from all participants.

Participants

The key inclusion criteria were as follows: HLA-A*24:02-positive, age ≥ 20 years, ESCC, neoadjuvant chemotherapy or chemoradiotherapy followed by curative resection classified as R0 according to the 7th edition of the Union for International Cancer Control (UICC), and histopathologically detected lymph node metastasis followed by lymph node dissection. The main exclusion criteria were serious concurrent disease (hepatic or renal disorder or cardiac, hematologic, respiratory, or metabolic disease) and laboratory test results indicating impaired blood, hepatic, or renal function within 28 days of enrollment. Other inclusion and exclusion criteria as well as methods for immunohistochemistry are presented in Online Resource 2.

Outcomes

The primary efficacy endpoint was relapse-free survival (RFS), which was defined as the time interval from the date of randomization to the date of relapse or death by any cause, whichever occurred first, or to the date when no relapse was confirmed. The secondary endpoints were overall survival (OS), disease-free survival (DFS), CTL induction rate (investigated within 12 weeks after the initial dose), and safety. DFS was defined as the time interval from the date of randomization to the date of recurrence, death by any cause, or the date of diagnosis of a secondary cancer, whichever occurred first, or the date of confirmation of no disease. RFS and DFS were evaluated at the central judgement committee, established independently from the sponsor and the medical institutions conducted this study. The CTL induction rate was calculated as the proportion of participants who showed positive CTL induction towards at least one of the five peptides. Positive CTL induction was defined as an increase in CTL intensity at any point after the baseline (before dosing on the date of the first dose). Imaging examinations were performed every 12 weeks. Clinical tests were performed at 1 week, 6 weeks, and 12 weeks after randomization, and thereafter every 12 weeks. Adverse events (AEs) were classified by system organ class and preferred terms using the Medical Dictionary for Regulatory Activities (MedDRA) version 23.0. Assessment of the injection site, physical examination, ECOG PS, vital signs, electrocardiogram, laboratory tests, and assessment of AEs according to CTCAE version 4.03 were performed. Of the reported AEs, treatment-emergent adverse events, defined as AEs occurring after the first dose of S-588410 or placebo, were used for safety analyses.

Enzyme-linked immunospot (ELISPOT) assay

For immune response monitoring, peripheral blood mononuclear cells (PBMCs) from participants in the S-588410 group were collected before vaccination (baseline) and at 8, 12, 32, 48, 96, and 108 weeks after vaccination and stored at − 80 °C until use. CTL induction, as an immunological response to each immunized peptide, was evaluated by counting spots in interferon-gamma-generating cells using an ELISPOT assay [9, 11]. After 2 weeks of in vitro PBMC stimulation with cognate peptides, cells were further incubated for 24 h in triplicate with TISI cells pulsed with each of the five peptides as stimulators. Subsequently, the number of peptide-specific spots was calculated based on the average of the triplicate measurements by subtracting the non-stimulated well (control) from the stimulated well containing the cognate peptide. According to a previously described scoring algorithm, the CTL response was classified into four grades (negative, 1+, 2+, and 3+) depending on the counts of peptide-specific spots [9].

Statistics

The target number of participants was set to 135 for each group, given that a one-sided significance level of 5% and power of 80% were assumed to detect a difference in RFS between the groups, considering the small number of dropouts. The assumptions used to calculate the required sample size are presented in additional information in Online Resource 3. For the intention-to-treat (ITT) population, the RFS, OS, and DFS of the S-588410 group were compared with those of the placebo group using the weighted log-rank test with Fleming–Harrington weights for (ρ, γ) = (0, 0.5), stratified by the histopathological classification of lymph node metastasis (pN1, pN2, or pN3) at a one-sided significance level of 0.05. For the primary analysis plan, a fixed-sequence procedure with OS was implemented in case of a significant difference in RFS for multiplicity adjustment with these comparisons, whereby the type I error rate for this primary analysis was controlled at ≤ 5%. The survival curves for RFS, OS, and DFS were estimated using the Kaplan–Meier method for each treatment group, and the median RFS, OS, and DFS and the associated 90% confidence interval (CI) were estimated. Considering the secondary endpoint, the CTL induction rate was defined as the proportion of patients who showed in vitro CTL induction toward at least one of the five antigens in the analysis population. Details of the analysis plan for CTL induction are described in Online Resource 3. Statistical analyses were performed using SAS software (version 9.4; SAS Institute Inc., Cary, NC, USA).

Results

A total of 276 participants were enrolled between May 2015 and March 2018, with 138 participants randomized to each of the S-588410 and placebo groups (ITT population) and followed up until March 2021. Two participants in the placebo group were mistreated with S-588410 (once each) and were included in the S-588410 group for safety analysis based on the study protocol (Fig., Online Resource 4). The two groups showed comparable features in terms of patient background (Table 1). Other baseline demographics, including clinical stage at diagnosis and antigen expression, were similar between the groups (Table, Online Resource 5; Fig., Online Resource 6).Table 1 Characteristics of the participants in the intention-to-treat (ITT) population

	S-588410 N = 138	Placebo N = 138	
Age (years), Mean ± standard deviation	65.0 ± 7.3	65.8 ± 8.2	
Sex	
 Male	109 (79.0)	114 (82.6)	
 Female	29 (21.0)	24 (17.4)	
Tumor lesion	
 Upper	19 (13.8)	22 (15.9)	
 Mid	67 (48.6)	66 (47.8)	
 Lower	52 (37.7)	50 (36.2)	
Neoadjuvant therapy	
 Chemotherapy	123 (89.1)	123 (89.1)	
 FP	66 (47.8)	59 (42.8)	
 DCF	56 (40.6)	62 (44.9)	
 FAP	1 (0.7)	2 (1.4)	
 Chemoradiotherapy	15 (10.9)	15 (10.9)	
Lymphadenectomy	
 2-field	32 (23.2)	27 (19.6)	
 3-field	106 (76.8)	111 (80.4)	
ypTNM_T at enrollment	
 T0	4 (2.9)	7 (5.1)	
 T1	31 (22.4)	39 (28.2)	
 T2	27 (19.6)	16 (11.6)	
 T3	72 (52.2)	76 (55.1)	
 T4	4 (2.8)	0	
ypTNM_N at enrollment	
 N0	5 (3.6)	3 (2.2)	
 N1	81 (58.7)	81 (58.7)	
 N2	40 (29.0)	41 (29.7)	
 N3	12 (8.7)	13 (9.4)	
ypTNM_M at enrollment	
 M0	116 (84.1)	116 (84.1)	
 M1	22 (15.9)	22 (15.9)	
ypStage at enrollment	
 Stage IIB	41 (29.7)	37 (26.8)	
 Stage IIIA	42 (30.4)	52 (37.7)	
 Stage IIIB	20 (14.5)	20 (14.5)	
 Stage IIIC	13 (9.4)	7 (5.1)	
 Stage IV	22 (15.9)	22 (15.9)	
Number of lymph node metastasis	
 pN1 (1–2)	78 (56.5)	80 (58.0)	
 pN2 (3–6)	44 (31.9)	43 (31.2)	
 pN3 (≥ 7)	16 (11.6)	15 (10.9)	
ECOG PS at baselinea	
 0	100 (72.5)	102 (73.9)	
 1	38 (27.5)	36 (26.1)	
N = Total number of participants in the relevant analysis; n = Number of participants in each category. % = Percentage of participants in each category relative to the total number of participants in the relevant analysis population. Data are presented as n (%) unless otherwise stated

ECOG PS Eastern Cooperative Oncology Group performance status, DCF docetaxel + cisplatin + 5-fluorouracil, FP 5-fluorouracil + cisplatin, FAP adriamycin + 5-fluorouracil + cisplatin

aBaseline was defined as the last available assessment obtained between screening and study visit 1

To evaluate the efficacy, RFS (primary endpoint) and OS (secondary endpoint) were estimated for the ITT population. The median RFS was 84.3 (90% CI 48.3–119.6) weeks and 84.1 weeks (48.1 weeks–not reached) in the S-588410 and placebo groups, respectively (Fig. 1A). The median OS was 236.3 weeks (187.7 weeks–not reached) and not reached (177.6 weeks–not reached) in the S-588410 and placebo groups, respectively (Fig. 1B). The median DFS (a secondary endpoint) was 83.3 (90% CI 47.1–118.1) weeks and 72.1 (47.1–163.9) weeks in the S-588410 and placebo groups, respectively. There were no significant differences in RFS (weighted log-rank test; one-sided P = 0.8156), OS (P = 0.6533), or DFS (weighted log-rank test; two-sided P = 0.3621) between the groups.Fig. 1 Kaplan–Meier estimates of relapse-free survival (A) and overall survival (B) in patients with ESCC treated with S-588410 and placebo. Weighted log-rank = weighted log-rank test with Fleming-Harrington class of weights for ρ = 0 and γ = 0.5

To evaluate immune responses in PBMCs during cancer vaccination, peptide-specific spots were measured using the ELISPOT assay. In the S-588410 group, the CTL induction rate against any of the five antigens at least once during the first 12 weeks of treatment was 98.5% (132/134 evaluated in the ITT population), with induction rates of 93.3%, 53.7%, 29.9%, 63.2%, and 65.7% for URLC10 (125/134), CDCA1 (72/134), KOC1 (40/134), DEPDC1 (84/133), and MPHOSPH1 (88/134) peptides, respectively. As shown in Online Resource 7A (Fig.), the highest proportion of participants (28.4%, 38/134) showing CTL induction within 12 weeks was attributed to the group that was positive for the three antigens. URLC10, DEPDC1, and MPHOSPH1 generated strong CTL induction (3+), whereas CDCA1 and KOC1 were associated with poor CTL induction (Fig., Online Resource 7B). Given the relatively low CTL induction rate of KOC1, the number of spots for the other four peptides is represented as scatter plots to evaluate the relationship between the two peptides in all combination patterns (Fig., Online Resource 7C). The number of specific spots (mean ± standard deviation) was 209 ± 232 for URLC10, 25 ± 67 for CDCA1, 51 ± 110 for DEPDC1, and 60 ± 114 for MPHOSPH1. Among the four spots, CDCA1 had a low mean number of spots, and patients with ≥ 100 specific spots (high CTL intensity) against CDCA1 had a relatively low number of specific spots against MPHOSPH1, and vice versa (Fig., Online Resource 7C).

As shown in the figure in Online Resource 4, 140 and 136 participants in the S-588410 and placebo groups, respectively, were included in the safety analysis. Treatment-related adverse events (TRAEs) occurred in 137 of 140 patients (97.9%) in the S-588410 group (239 events), and in 116 of 136 patients (85.3%) in the placebo group (228 events). Deaths during the treatment period occurred in two patients in the S-588410 group (one death due to malnutrition and aspiration pneumonia, one death due to myocardial infarction) and one patient in the placebo group (one death due to a malignant neoplasm of unknown primary site). All events were determined to be unrelated to the study drug. Table 2 summarizes TRAEs with an incidence of ≥ 1%. In both groups, the most frequent TRAE was injection site reaction. Grade 3 injection-site reactions (12.9%, 18/140 in the safety analysis population) were observed only in the S-588410 group. Other grade 3 TRAEs included injection-site infection, reduced neutrophil count, and reduced white blood cell count in the S-588410 group (0.7% each in 1/140) and hypokalemia in the placebo group (0.7% each in 1/136). TRAEs resulting in treatment withdrawal included eczema and elevated eosinophil counts in the S-588410 group (0.7% each in 1/140) and nausea and malaise in the placebo group (0.7% each in 1/136). No grade 4 or 5 TRAEs were reported.Table 2 TRAEs in the S-588410 and placebo groups (incidence ≥ 1% each in the group, safety analysis population)

	S-588410 N = 140, n (E) %	Placebo N = 136, n (E) %	
Any	137 (239) 97.9	116 (228) 85.3	
Injection-site reaction	137 (177) 97.9	113 (208) 83.1	
Pyrexia	12 (28) 8.6	1 (1) 0.7	
Injection-site infection	3 (3) 2.1	0	
Malaise	2 (2) 1.4	2 (2) 1.5	
Hypersensitivity	2 (14) 1.4	0	
Rash	2 (2) 1.4	1 (1) 0.7	
Gynecomastia	2 (2) 1.4	0	
N = Total number of participants in the relevant analysis population. n = Number of participants with an adverse event of that type; each participant was counted only once. % = Percentage of participants in the relevant analysis population who experienced an adverse event of that type. E = Number of adverse events of that type; that is, a participant experienced multiple adverse events counted multiple times

Treatment-emergent adverse events were classified by system organ class and preferred terms, using the Medical Dictionary for Regulatory Activities (MedDRA) Version 23.0

TRAE treatment-related adverse event

Based on subgroup analysis by tumor lesion, S-588410-treated participants had significantly longer survival than placebo-treated participants with upper thoracic ESCC (Fig., Online Resource 8). In the subgroup analysis based on stratification factors, no significantly prolonged survival was observed in the S-588410 group according to the histopathological classification of lymph node metastasis (pN1, pN2, or pN3) and classification of neoadjuvant therapy (Figs., Online Resource 9 and 10). Analysis of histopathological and clinical TNM classification and stage revealed that the S-588410 group was not associated with significantly prolonged survival compared to the placebo group (data not shown). As an exploratory analysis, we examined the relationship between the CTL intensity and survival. Patients with ≥ 100 peptide-specific spots (high CTL intensity population in Online Resource 7C) for each CDCA1 and MPHOSPH1 peptide tended to exhibit prolonged RFS and OS (Fig., Online Resource 11A, B) in the late phase, although the difference was not significant. Analysis of KOC1 was not performed because none of the patients had ≥ 100 peptide-specific spots. Similar results were obtained when analyzing patients with a positive CTL induction or those with a 3 + CTL grade (data not shown). In the S-588410 group, participants (n = 18) with grade 3 injection-site reactions had a longer RFS and OS than those with grade < 3 reactions (Fig., Online Resource 11C, D).

Discussion

To the best of our knowledge, this phase 3 study is the first to investigate the efficacy, immune response, and safety of the multi-peptide cancer vaccine S-588410 as an adjuvant monotherapy after curative resection in patients with ESCC. No statistically significant differences were observed in RFS or OS between the S-588410 and placebo groups. Conversely, prolonged survival was observed in a subgroup of patients with upper thoracic ESCC, grade 3 injection-site reactions, and a high immune response, with ≥ 100 peptide-specific spots for CDCA1 and MPHOSPH1.

Regarding immune response, the CTL induction rate of each peptide in S-588410 in the current phase 3 study was similar to levels achieved in the phase 2 bladder cancer study of S-588410 [17]. However, compared with the results of the phase 2 esophageal cancer study using three peptides (URLC10, CDCA1, and KOC1), despite the similar CTL induction rates for URLC10 (93.3% [125/134] in the phase 3 study and 87.9% [29/33] in the phase 2 study), induction rates of CDCA1 and KOC1 in the current study were lower than those in the phase 2 study (53.7% [72/134] in the phase 3 study and 90.9% [30/33] in the phase 2 study for CDCA1; 29.9% [40/134] in the phase 3 study and 54.5% [18/33] in the phase 2 study for KOC1) [10]. Considering the grade of CTL response, the proportion of patients with a high grade (3+) for CDCA1 was lower in the phase 3 study than in the phase 2 ESCC study [10]. Treatment with a cancer peptide vaccine has been associated with an augmented CTL induction (as an immune response) and survival benefits [9–11, 18–24]. These results suggest that a high CTL response for CDCA1 critically affects survival efficacy, although differences in study design, such as the control group and number of administered peptides between the phase 2 ESCC study [10] and current phase 3 study, need to be considered.

Given that the number of peptide-specific spots could be employed as an evaluation criterion for the immune response [24, 25], we measured the difference in survival between patients with ≥ 100 peptide-specific spots and those with < 100 spots for each peptide. Reportedly, patients with > 100 spots for TTK, LY6K (also known as URLC10), and IMP-3 (also known as KOC1) post-vaccination exhibit clinical response [25]. Although we failed to detect statistical significance in our study, patients with ≥ 100 peptide-specific spots for CDCA1 and MPHOSPH1 tended to exhibit prolonged survival. However, limited reports are available regarding the criteria for the number of peptide-specific spots, thus, it may be necessary to evaluate this number as a novel indicator. Furthermore, patients with a high number of specific spots for both CDCA1 and MPHOSPH1 were rarely detected, although some patients exhibited numerous spots for the other peptide pairs (Fig., Online Resource 7C). The precise reason underlying the limited number of patients exhibiting high numbers of specific spots for both CDCA1 and MPHOSPH1 remains unknown, despite peptides from CDCA1 and MPHOSPH1 being categorized as “strong” epitopes according to peptide–HLA-binding prediction by NetMHC-4.0 [26, 27]. Further investigations are warranted to determine whether competition among co-administered peptides could explain the restricted CTL induction. In the presence of such competition, appropriate selection of a combination of peptides may be essential for mixed-peptide cancer vaccines. In some studies, each peptide was injected separately as a multipeptide vaccine [9, 19]. However, a previous study found no significant difference in immune response induction between multiple-site injections of each peptide and single-site injections of a cocktail peptide [18]. Although the CDCA1 peptide has been explored in other clinical studies [19–22], S-588410 is the first cocktail vaccine in which CDCA1 was mixed with MPHOSPH1. Thus, before initiating a pivotal study, it is necessary to establish whether the CTL response level for each peptide is reproducible compared with that observed in previous studies, especially when considering new multipeptide formulations.

In a pre-surgical study conducted on esophageal cancer, increased expression of PD-L1 was observed in tumors following administration of a cancer vaccine [16]. In patients in whom a cancer vaccine alone is ineffective, the induction of PD-L1 expression is thought to be the cause of the reduced efficacy, so the combination of a cancer vaccine with a PD-(L)1 antibody is expected to be effective. In particular, a synergistic effect may be seen in patients whose tumor immunity is not very active. In addition, S-588410 administration in a pre-surgical study on esophageal cancer has also shown to induce functional CD8 + and CD4 + TILs, specifically CD8 + PD-1 + and CD4 + PD-1 + cells [16]. This induction of TILs may be associated with an increase in interferon-gamma production. Consequently, it is possible that this increased interferon-gamma production from TILs may lead to an upregulation of PD-L1 expression in the tumor tissue, which allows cancer cells to evade immune detection. Checkpoint inhibitors, such as pembrolizumab or nivolumab, can block the PD-L1/PD-1 interaction, reactivating the immune response against cancer cells. Thus, combining S-588410 administration with checkpoint inhibitors may further enhance the efficacy of these immunotherapies in esophageal cancer treatment. Based on the above, it is expected that the combination with the standard therapy, PD-1 antibody, will be clinically significant.

Although various phase 3 trials have reported the efficacy of cancer peptide vaccines [28–31], factors associated with survival remain poorly established. In this trial, patient demographics, and biomarkers, including CTL responses, were evaluated in patients; however, none of these were associated with survival. In contrast, we observed a substantial survival benefit afforded by S-588410 in patients with upper thoracic ESCC. Although the mechanism of this benefit requires further investigation, our findings might be valuable as a possible treatment option since it has been reported that upper thoracic ESCC had worse survival than those with mid- and lower thoracic ESCC [32] and no consensus for the optimal treatment of upper thoracic ESCC has been provided [3]. Moreover, we observed that patients with grade 3 injection-site reactions in the S-588410 group showed significantly prolonged survival, consistent with the findings of previous cancer vaccine trials [18, 19, 23, 28]. Thus, a strong local immune reaction at the injection site could be a prognostic factor for cancer vaccine treatment. One possible mechanism of action of cancer peptide vaccines is induction of potent immune responses. Accordingly, it is crucial to develop a method to reinforce CTL induction and/or to select patients for whom cancer peptide vaccines are immunologically beneficial.

Nevertheless, this study had some limitations. First, the S-588410 comprises only HLA-A*24:02-restricted peptides. Therefore, we speculate that our findings are limited to HLA-A*24:02-positive individuals (most common in the Japanese population) owing to the use of HLA-A*24:02-restricted peptides. Second, validating the analysis of the number of peptide-specific spots remains a challenge, given the few patients with high CTL intensity and limited number of comparable reports.

In conclusion, although the current study failed to meet its primary endpoint, our findings revealed that S-588410 may confer a survival benefit to patients with ESCC capable of developing an immune response upon vaccination with certain key peptides. Further studies are required to define the subset of patients with a high probability of developing an appropriate CTL response.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 1937 KB)

Acknowledgements

We thank the patients who participated in the study. We also thank the investigators and clinical study teams for facilitating this study at all centers in Japan. We also thank Ken-ichi Setsukinai (Shionogi & Co., Ltd., Ph.D., CMPP) for his editorial support.

Author contributions

TY, YD, MY, KM, YM, KI, and THi were involved in the conception and design of the study. MT, YD, HM, MY, TY, KM, and YK collected the data. JP and THa were involved in data analysis. All authors were involved in the interpretation of the data and writing, review, and revision of this manuscript. All authors approved the final manuscript prior to publication. Scientific representatives of sponsors participated in the study design. Data collected by the investigators were analyzed by representatives of the sponsor. All authors, including those representing the sponsor, had full access to all study data.

Funding

The work was supported by OncoTherapy Science, Inc. and Shionogi & Co., Ltd.

Data sharing

The data obtained in this study are not available in a public repository, because Shionogi & Co., Ltd. takes suitable measures to protect personal information and the sponsor’s intellectual property. The protected information is tailored to a specific request.

Declarations

Ethical Statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.

Conflict of interest

TM reports honoraria from Ono Pharmaceutical, MSD, and research funding from Takeda Pharmaceutical. YK reports grants to his institution from Chugai Pharmaceutical, Taiho Pharmaceutical, Asahi Kasei Pharma, Otsuka Pharmaceutical, Tsumura, Kaken Pharmaceutical, Sumitomo Pharma, Eisai, Otsuka Pharmaceutical Factory, Kyowa Kirin, Takeda Pharmaceutical, Teijin Pharma, and Kowa; and personal fee from Asahi Kasei Pharma, Astra Zeneca, Ethicon, Ono Pharmaceutical, Otsuka Pharmaceutical Factory, Olympus, Cardinal Health, Shionogi & Co., Ltd., Taiho Pharmaceutical, Chugai Pharmaceutical, Bristol-Myers Squibb, MSD, Smith & Nephew, Kaken Pharmaceutical, Aska Pharmaceutical, Miyarisan Pharmaceutical, Toray Industries, Daiichi Sankyo, Chugai Foundation for Innovation Drug Discovery Science, Nippon Kayaku, EA Pharma, Intuitive Surgical, Takeda Pharmaceutical, Sysmex, Tsumura, AI Medical Service, Kowa, and Eisai; and Joint Research Laboratory for Development and Education of Innovative Medical Technology for Sysmex and Medicaroid; and Editor in Chief of Annals of Gastroenterological Surgery issued by The Japanese Society of Gastroenterological Surgery. KM reports honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Eli Lilly, Daiichi Sankyo, Taiho Pharmaceutical, Takeda Pharmaceutical and MSD; and research funding from PRA Health Science, Astellas, Novartis Pharma, Amgen, Sanofi, Taiho Pharmaceutical, MSD, Chugai Pharmaceutical and Paraxel International. YD reports that his institution received a research grant from Shionogi & Co., Ltd outside of this clinical study. JP is an employee of OncoTherapy Science Inc. THi is an employee of OncoTherapy Science, Inc. and an assigned employee of Cancer Precision Medicine, Inc, and has stock options of OncoTherapy Science, Inc.; and patent pending (WO 2022/149295). THa is an employee of Shionogi & Co., Ltd., and has stocks of Shionogi & Co., Ltd. YM was an employee of Shionogi & Co., Ltd. when the study was conducted, and has minor stocks of Shionogi & Co., Ltd.; and reports participation on Data safety Monitoring Board and Advisory Board that Shionogi & Co., Ltd. held. KI, and MI were also employees of Shionogi & Co., Ltd. when the study was conducted. All other authors declare that they have no conflict of interest.

Informed consent

Informed consent or substitute for it was obtained from all patients for being included in the study.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Sung H Ferlay J Siegel RL Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2021 71 209 249 10.3322/caac.21660 33538338
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.33538338 10.3322/caac.21660
2. Morgan E Soerjomataram I Rumgay H The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020 Gastroenterology 2022 163 649 58.e2 10.1053/j.gastro.2022.05.054 35671803
Morgan E, Soerjomataram I, Rumgay H, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology. 2022;163:649-58.e2.35671803 10.1053/j.gastro.2022.05.054
3. Ajani JA D’Amico TA Bentrem DJ Esophageal and esophagogastric junction cancers, version 2.2019, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw 2019 17 855 883 10.6004/jnccn.2019.0033 31319389
Ajani JA, D’Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:855–83.31319389 10.6004/jnccn.2019.0033
4. Ando N Iizuka T Ide H Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204 J Clin Oncol 2003 21 4592 4596 10.1200/JCO.2003.12.095 14673047
Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol. 2003;21:4592–6.14673047 10.1200/JCO.2003.12.095
5. Ando N Kato H Igaki H A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus JCOG9907) Ann Surg Oncol 2012 19 68 74 10.1245/s10434-011-2049-9 21879261
Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus JCOG9907). Ann Surg Oncol. 2012;19:68–74.21879261 10.1245/s10434-011-2049-9
6. Kadono T Yamamoto S Kato K Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer Jpn J Clin Oncol 2022 52 1089 1096 36047845
Kadono T, Yamamoto S, Kato K. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer. Jpn J Clin Oncol. 2022;52:1089–96.36047845
7. Chen L Han X Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future J Clin Invest 2015 125 3384 3391 10.1172/JCI80011 26325035
Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125:3384–91.26325035 10.1172/JCI80011
8. Nakaoka H Inoue I Distribution of HLA haplotypes across Japanese Archipelago: similarity, difference and admixture J Hum Genet 2015 60 683 690 10.1038/jhg.2015.90 26202576
Nakaoka H, Inoue I. Distribution of HLA haplotypes across Japanese Archipelago: similarity, difference and admixture. J Hum Genet. 2015;60:683–90.26202576 10.1038/jhg.2015.90
9. Kono K Iinuma H Akutsu Y Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens J Transl Med 2012 10 141 10.1186/1479-5876-10-141 22776426
Kono K, Iinuma H, Akutsu Y, et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 2012;10:141.22776426 10.1186/1479-5876-10-141
10. Yasuda T Nishiki K Hiraki Y Phase II adjuvant cancer-specific vaccine therapy for esophageal cancer patients curatively resected after preoperative therapy with pathologically positive nodes; possible significance of tumor immune microenvironment in its clinical effects Ann Surg 2022 275 e155 e162 10.1097/SLA.0000000000003880 33055588
Yasuda T, Nishiki K, Hiraki Y, et al. Phase II adjuvant cancer-specific vaccine therapy for esophageal cancer patients curatively resected after preoperative therapy with pathologically positive nodes; possible significance of tumor immune microenvironment in its clinical effects. Ann Surg. 2022;275:e155–62.33055588 10.1097/SLA.0000000000003880
11. Obara W Eto M Mimata H A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder Ann Oncol 2017 28 798 803 10.1093/annonc/mdw675 27998971
Obara W, Eto M, Mimata H, et al. A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder. Ann Oncol. 2017;28:798–803.27998971 10.1093/annonc/mdw675
12. Murahashi M Hijikata Y Yamada K Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors Clin Immunol 2016 166–167 48 58 10.1016/j.clim.2016.03.015 27072896
Murahashi M, Hijikata Y, Yamada K, et al. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 2016;166–167:48–58.27072896 10.1016/j.clim.2016.03.015
13. Harao M Hirata S Irie A HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL Int J Cancer 2008 123 2616 2625 10.1002/ijc.23823 18770861
Harao M, Hirata S, Irie A, et al. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int J Cancer. 2008;123:2616–25.18770861 10.1002/ijc.23823
14. Longo DL Tumor heterogeneity and personalized medicine N Engl J Med 2012 366 956 957 10.1056/NEJMe1200656 22397658
Longo DL. Tumor heterogeneity and personalized medicine. N Engl J Med. 2012;366:956–7.22397658 10.1056/NEJMe1200656
15. Cecco S Muraro E Giacomin E Cancer vaccines in phase II/III clinical trials: state of the art and future perspectives Curr Cancer Drug Targets 2011 11 1 85 102 10.2174/156800911793743664 21062241
Cecco S, Muraro E, Giacomin E, et al. Cancer vaccines in phase II/III clinical trials: state of the art and future perspectives. Curr Cancer Drug Targets. 2011;11(1):85–102.21062241 10.2174/156800911793743664
16. Daiko H Marafioti T Fujiwara T Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients Cancer Immunol Immunother 2020 69 2247 2257 10.1007/s00262-020-02619-3 32500232
Daiko H, Marafioti T, Fujiwara T, et al. Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients. Cancer Immunol Immunother. 2020;69:2247–57.32500232 10.1007/s00262-020-02619-3
17. Shimizu N Hussain SA Obara W A phase 2 study of S-588410 maintenance monotherapy for platinum-treated advanced or metastatic urothelial carcinoma Bladder Cancer 2022 8 179 192 10.3233/BLC-211592 38993370
Shimizu N, Hussain SA, Obara W, et al. A phase 2 study of S-588410 maintenance monotherapy for platinum-treated advanced or metastatic urothelial carcinoma. Bladder Cancer. 2022;8:179–92.38993370 10.3233/BLC-211592
18. Hazama S Nakamura Y Takenouchi H A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome J Transl Med 2014 12 63 10.1186/1479-5876-12-63 24612787
Hazama S, Nakamura Y, Takenouchi H, et al. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J Transl Med. 2014;12:63.24612787 10.1186/1479-5876-12-63
19. Yoshitake Y Fukuma D Yuno A Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS Clin Cancer Res 2015 21 312 321 10.1158/1078-0432.CCR-14-0202 25391695
Yoshitake Y, Fukuma D, Yuno A, et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res. 2015;21:312–21.25391695 10.1158/1078-0432.CCR-14-0202
20. Suzuki H Fukuhara M Yamaura T Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer J Trans Med 2013 11 97 10.1186/1479-5876-11-97
Suzuki H, Fukuhara M, Yamaura T, et al. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J Trans Med. 2013;11:97.10.1186/1479-5876-11-97
21. Okuyama R Aruga A Hatori T Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients Oncoimmunology 2013 2 e27010 10.4161/onci.27010 24498547
Okuyama R, Aruga A, Hatori T, et al. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Oncoimmunology. 2013;2: e27010.24498547 10.4161/onci.27010
22. Obara W Sato F Takeda K Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer Cancer Sci 2017 108 1452 1457 10.1111/cas.13278 28498618
Obara W, Sato F, Takeda K, et al. Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. Cancer Sci. 2017;108:1452–7.28498618 10.1111/cas.13278
23. Fujiwara Y Okada K Omori T Multiple therapeutic peptide vaccines for patients with advanced gastric cancer Int J Oncol 2017 50 1655 1662 10.3892/ijo.2017.3955 28393243
Fujiwara Y, Okada K, Omori T, et al. Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int J Oncol. 2017;50:1655–62.28393243 10.3892/ijo.2017.3955
24. Gridelli C Ciuleanu T Domine M Clinical activity of a htert (vx–001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial Br J Cancer 2020 122 1461 1466 10.1038/s41416-020-0785-y 32210365
Gridelli C, Ciuleanu T, Domine M, et al. Clinical activity of a htert (vx–001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial. Br J Cancer. 2020;122:1461–6.32210365 10.1038/s41416-020-0785-y
25. Kono K Mizukami Y Daigo Y Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T cell responses and clinical responses in advanced esophageal cancer Cancer Sci 2009 100 1502 1509 10.1111/j.1349-7006.2009.01200.x 19459850
Kono K, Mizukami Y, Daigo Y, et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 2009;100:1502–9.19459850 10.1111/j.1349-7006.2009.01200.x
26. Andreatta M Nielsen M Gapped sequence alignment using artificial neural networks: application to the MHC class I system Bioinformatics 2016 32 511 517 10.1093/bioinformatics/btv639 26515819
Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 2016;32:511–7.26515819 10.1093/bioinformatics/btv639
27. Nielsen M Lundegaard C Worning P Reliable prediction of T-cell epitopes using neural networks with novel sequence representations Protein Sci 2003 12 1007 1017 10.1110/ps.0239403 12717023
Nielsen M, Lundegaard C, Worning P, et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 2003;12:1007–17.12717023 10.1110/ps.0239403
28. Yamaue H Tsunoda T Tani M Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC study Cancer Sci 2015 106 883 890 10.1111/cas.12674 25867139
Yamaue H, Tsunoda T, Tani M, et al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC study. Cancer Sci. 2015;106:883–90.25867139 10.1111/cas.12674
29. Mittendorf EA Lu B Melisko M Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial Clin Cancer Res 2019 25 4248 4254 10.1158/1078-0432.CCR-18-2867 31036542
Mittendorf EA, Lu B, Melisko M, et al. Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial. Clin Cancer Res. 2019;25:4248–54.31036542 10.1158/1078-0432.CCR-18-2867
30. Middleton G Silcocks P Cox T Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial Lancet Oncol 2014 15 829 840 10.1016/S1470-2045(14)70236-0 24954781
Middleton G, Silcocks P, Cox T, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15:829–40.24954781 10.1016/S1470-2045(14)70236-0
31. Rini BI Stenzl A Zdrojowy R IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial Lancet Oncol 2016 17 1599 1611 10.1016/S1470-2045(16)30408-9 27720136
Rini BI, Stenzl A, Zdrojowy R, et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:1599–611.27720136 10.1016/S1470-2045(16)30408-9
32. Rice TW Rusch VW Apperson-Hansen C Worldwide esophageal cancer collaboration Dis Esophagus 2009 22 1 8 10.1111/j.1442-2050.2008.00901.x 19196264
Rice TW, Rusch VW, Apperson-Hansen C, et al. Worldwide esophageal cancer collaboration. Dis Esophagus. 2009;22:1–8.19196264 10.1111/j.1442-2050.2008.00901.x
